2017 Q3 Form 10-Q Financial Statement
#000119312517254597 Filed on August 10, 2017
Income Statement
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| Revenue | $305.0K | $305.0K | $305.0K |
| YoY Change | 0.0% | 0.0% | 1694.12% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.560M | $4.290M | $2.810M |
| YoY Change | 8.87% | 52.67% | -14.59% |
| % of Gross Profit | |||
| Research & Development | $12.19M | $9.862M | $6.131M |
| YoY Change | -0.7% | 60.85% | 169.97% |
| % of Gross Profit | |||
| Depreciation & Amortization | $150.0K | $70.00K | $10.00K |
| YoY Change | 600.0% | -111.11% | |
| % of Gross Profit | |||
| Operating Expenses | $15.75M | $14.15M | $8.939M |
| YoY Change | 1.34% | 58.26% | 60.8% |
| Operating Profit | -$15.45M | -$13.84M | -$8.634M |
| YoY Change | 1.37% | 60.32% | 55.79% |
| Interest Expense | $411.0K | $290.0K | $276.0K |
| YoY Change | 53.36% | 5.07% | -185.71% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $358.0K | $203.0K | $276.0K |
| YoY Change | 33.09% | -26.45% | -141.07% |
| Pretax Income | -$15.09M | -$13.64M | -$8.360M |
| YoY Change | 0.8% | 63.16% | 34.62% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$15.09M | -$13.64M | -$8.358M |
| YoY Change | 0.79% | 63.18% | 34.5% |
| Net Earnings / Revenue | -4946.89% | -4471.8% | -2740.33% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$678.5K | -$699.5K | -$470.5K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 22.22M shares | 18.26M shares | 17.78M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $121.5M | $132.0M | $125.9M |
| YoY Change | 4.74% | 4.85% | 174.89% |
| Cash & Equivalents | $20.73M | $22.99M | $14.44M |
| Short-Term Investments | $100.8M | $109.0M | $111.5M |
| Other Short-Term Assets | $1.900M | $1.800M | $1.200M |
| YoY Change | 90.0% | 50.0% | 140.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $124.0M | $134.2M | $127.4M |
| YoY Change | 5.72% | 5.33% | 175.71% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $286.0K | $260.0K | $304.0K |
| YoY Change | 1.06% | -14.47% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $236.0K | $239.0K | $173.0K |
| YoY Change | 31.84% | 38.15% | -42.33% |
| Total Long-Term Assets | $522.0K | $499.0K | $477.0K |
| YoY Change | 12.99% | 4.61% | 59.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $124.0M | $134.2M | $127.4M |
| Total Long-Term Assets | $522.0K | $499.0K | $477.0K |
| Total Assets | $124.5M | $134.7M | $127.9M |
| YoY Change | 5.75% | 5.33% | 174.96% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.246M | $3.362M | $1.588M |
| YoY Change | 11.74% | 111.71% | 98.5% |
| Accrued Expenses | $10.70M | $6.900M | $3.700M |
| YoY Change | 81.36% | 86.49% | 76.19% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $14.21M | $11.51M | $6.553M |
| YoY Change | 55.32% | 75.57% | -8.99% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $267.0K | $214.0K | $232.0K |
| YoY Change | 19.73% | -7.76% | -98.67% |
| Total Long-Term Liabilities | $13.57M | $13.82M | $15.06M |
| YoY Change | -7.97% | -8.22% | -35.63% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $14.21M | $11.51M | $6.553M |
| Total Long-Term Liabilities | $13.57M | $13.82M | $15.06M |
| Total Liabilities | $27.78M | $25.33M | $21.62M |
| YoY Change | 16.25% | 17.18% | -29.13% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$347.0M | -$331.9M | -$279.5M |
| YoY Change | 17.84% | 18.75% | |
| Common Stock | $443.7M | $441.2M | $385.6M |
| YoY Change | 14.29% | 14.44% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $96.71M | $109.3M | $106.2M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $124.5M | $134.7M | $127.9M |
| YoY Change | 5.75% | 5.33% | 174.96% |
Cashflow Statement
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$15.09M | -$13.64M | -$8.358M |
| YoY Change | 0.79% | 63.18% | 34.5% |
| Depreciation, Depletion And Amortization | $150.0K | $70.00K | $10.00K |
| YoY Change | 600.0% | -111.11% | |
| Cash From Operating Activities | -$10.18M | -$11.80M | -$6.890M |
| YoY Change | -11.09% | 71.26% | 72.25% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$40.00K | $0.00 | -$80.00K |
| YoY Change | -20.0% | -100.0% | 700.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $6.960M | -$36.60M | -$560.0K |
| YoY Change | -14.18% | 6435.71% | -96.75% |
| Cash From Investing Activities | $6.920M | -$36.60M | -$620.0K |
| YoY Change | -14.04% | 5803.23% | -96.4% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.010M | 48.98M | -1.230M |
| YoY Change | -40.94% | -4082.11% | -106.58% |
| NET CHANGE | |||
| Cash From Operating Activities | -10.18M | -11.80M | -6.890M |
| Cash From Investing Activities | 6.920M | -36.60M | -620.0K |
| Cash From Financing Activities | 1.010M | 48.98M | -1.230M |
| Net Change In Cash | -2.250M | 580.0K | -8.740M |
| YoY Change | 33.14% | -106.64% | 244.09% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$10.18M | -$11.80M | -$6.890M |
| Capital Expenditures | -$40.00K | $0.00 | -$80.00K |
| Free Cash Flow | -$10.14M | -$11.80M | -$6.810M |
| YoY Change | -11.05% | 73.27% | 70.68% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
22219978 | shares |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14441000 | |
| CY2016Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
| CY2017Q2 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
6923000 | |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
134167000 | |
| CY2017Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
36000 | |
| CY2017Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
441218000 | |
| CY2017Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3362000 | |
| CY2017Q2 | us-gaap |
Assets
Assets
|
134666000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
74000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
38000 | |
| CY2017Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
106931000 | |
| CY2017Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
106967000 | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22988000 | |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
260000 | |
| CY2017Q2 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
101000 | |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-331919000 | |
| CY2017Q2 | us-gaap |
Short Term Investments
ShortTermInvestments
|
106967000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4111000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q2 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
504000 | |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22219843 | shares |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1220000 | |
| CY2017Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
| CY2017Q2 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
2007000 | |
| CY2017Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
13610000 | |
| CY2017Q2 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
419000 | |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
25329000 | |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
134666000 | |
| CY2017Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
13824000 | |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
11505000 | |
| CY2017Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
239000 | |
| CY2017Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
214000 | |
| CY2017Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
286000 | |
| CY2017Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
109337000 | |
| CY2017Q2 | us-gaap |
Supplies
Supplies
|
457000 | |
| CY2017Q2 | sndx |
Reimbursable Costs
ReimbursableCosts
|
438000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23179000 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
6771000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
108510000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
56000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
389374000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2375000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
109013000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
67000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
11000 | |
| CY2016Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
81430000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
81486000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
23844000 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1220000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
18215181 | shares |
| CY2016Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
1630000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
14220000 | |
| CY2016Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
306000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
24874000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
109013000 | |
| CY2016Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
14508000 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10366000 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
243000 | |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
288000 | |
| CY2016Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
202000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3029000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
168000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
260000 | |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
151000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-305293000 | |
| CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
81486000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
84139000 | |
| CY2016Q4 | us-gaap |
Supplies
Supplies
|
461000 | |
| CY2016Q4 | sndx |
Reimbursable Costs
ReimbursableCosts
|
262000 | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2825000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2825000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
41000 | ||
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-856000 | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001395937 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26630000 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
79000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.41 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-06-30 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
SYNDAX PHARMACEUTICALS INC | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8215000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-610000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
800000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
122000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1082000 | ||
| us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-50000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
549000 | ||
| us-gaap |
Licenses Revenue
LicensesRevenue
|
610000 | ||
| us-gaap |
Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
|
-20000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>1. Nature of Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Syndax Pharmaceuticals, Inc. (the Company) is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. The Company’s lead product candidate, entinostat, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to entinostat when given in combination with exemestane following positive results from the Company’s ENCORE 301 Phase 2b clinical trial. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, the Company is evaluating entinostat as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for <font style="WHITE-SPACE: nowrap">non-small</font> cell lung cancer, melanoma and microsatellite stable colorectal cancer; with Genentech, Inc. for triple negative breast cancer; and with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. for ovarian cancer. The Company’s second product candidate, SNDX-6352, is a monoclonal antibody that targets the colony stimulating <font style="WHITE-SPACE: nowrap">factor-1</font> receptor to enhance the body’s immune response against tumors that have shown sensitivity to immunotherapy. The Company is evaluating SNDX-6352 in a Phase 1 clinical trial. The Company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In March 2016, the Company completed its initial public offering (“IPO”) whereby it sold 4,809,475 shares of common stock at the initial public offering price of $12.00 per share, which included 409,475 shares issued pursuant to the underwriters’ partial exercise of their over-allotment option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were $50.5 million, net of underwriting discounts and commissions of $4.0 million and offering expenses of $3.1 million. Upon the closing of the IPO, all outstanding shares of the Company’s outstanding convertible preferred stock converted into 12,872,551 shares of common stock; and the Company’s outstanding warrant liability to purchase 357,840 shares of the Company’s common stock valued at $4.6 million was reclassified to additional <font style="WHITE-SPACE: nowrap">paid-in</font> capital. In connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on September 28, 2015 and February 24, 2016, respectively. Pursuant to the amended and restated certificate of incorporation, the Company is now authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> In May 2017, the Company completed a <font style="WHITE-SPACE: nowrap">follow-on</font> public offering whereby the Company sold 3,950,190 shares of common stock at a price of $13.25 per share, which included 200,190 shares issued pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $48.7 million, net of underwriting discounts and commissions and estimated offering expenses payable by the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company’s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be two or more years before either entinostat or SNDX-6352 is approved, if ever, and the Company begins to generate revenue from sales of either entinostat or SNDX-6352. Accordingly, management expects to incur substantial losses on the ongoing development of entinostat and SNDX-6352 and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The Company’s management believes that the cash, cash equivalents and short-term investments balances as of June 30, 2017 should enable the Company to maintain its planned operations for at least the next 12 months. The Company’s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds are not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities.</p> </div> | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-25492000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-24468000 | ||
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-26610000 | ||
| CY2016Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-8394000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
27629000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
49104000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-26610000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-27019000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
409000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-20000 | ||
| us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-8000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-140000 | ||
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
87989000 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
48836000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
62447000 | ||
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-1000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
269000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
19414000 | ||
| us-gaap |
Sales Revenue Net
SalesRevenueNet
|
610000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2825000 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
45930 | shares | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
269000 | ||
| us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
59000 | ||
| dei |
Trading Symbol
TradingSymbol
|
SNDX | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
18868089 | shares | |
| sndx |
Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
|
161000 | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p> </div> | ||
| sndx |
Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
|
59000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2969000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
51000 | ||
| us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-8738000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-18524000 | ||
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
328941000 | ||
| us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
57000 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.91 | ||
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1703000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7080000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-610000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-54000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1707000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
394000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
420000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
2000 | ||
| us-gaap |
Licenses Revenue
LicensesRevenue
|
610000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-47761000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-13293000 | ||
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-21286000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
17997000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
52316000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-18688000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17387000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1301000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
164000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-18000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
206000 | ||
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
109932000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
62377000 | ||
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-2000 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
52318000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10917000 | ||
| us-gaap |
Sales Revenue Net
SalesRevenueNet
|
610000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2969000 | ||
| us-gaap |
Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
|
2598000 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
11155525 | shares | |
| sndx |
Fair Value Adjustment Of Warrants And Derivative Liabilities
FairValueAdjustmentOfWarrantsAndDerivativeLiabilities
|
-1720000 | ||
| sndx |
Reclassification Of Common Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital
|
4551000 | ||
| sndx |
Issuance Costs Included In Accounts Payable And Accrued Expenses
IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
|
170000 | ||
| sndx |
Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
|
21000 | ||
| CY2016Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
779000 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | |
| CY2016Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2808000 | |
| CY2016Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
276000 | |
| CY2016Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
305000 | |
| CY2016Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-8358000 | |
| CY2016Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
8939000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8358000 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8634000 | |
| CY2016Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
276000 | |
| CY2016Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-36000 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6131000 | |
| CY2016Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
305000 | |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
17769514 | shares |
| CY2017Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1448000 | |
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13601000 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.70 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4285000 | |
| CY2017Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
290000 | |
| CY2017Q2 | us-gaap |
Licenses Revenue
LicensesRevenue
|
305000 | |
| CY2017Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13639000 | |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
14147000 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13639000 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13842000 | |
| CY2017Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
203000 | |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
38000 | |
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-87000 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9862000 | |
| CY2017Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
305000 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19497581 | shares |
